Antithrombotic Therapy in Elderly Patients with Atrial Fibrillation: The State of the Problem in the Real Clinical Practice of a Family Medicine Doctor

Introduction. The research aimed at studying the efficacy and safety of anticoagulant therapy in patients with atrial fibrillation (AF), especially in older age groups, is now increasingly relevant.

The aim of the study is to analyze the situation with prescribing anticoagulant therapy in elderly and senile persons with atrial fibrillation in real clinical practice and to demonstrate the possibility of improving the quality of observation and management of a group of patients as part of the work of a specialized team.

Materials and methods. A total of 2,770 medical records of outpatient patients with atrial fibrillation were studied for the period from 2017 to 2019. Of this number, 320 patients with AF of nonvalvular etiology were selected, the average age of which was 70.3 ± 8.15 years. There were 270 women and 50 men. An observational prospective study in 45 elderly and senile patients with AF of non-valvular etiology was carried out by a team of specialized doctors for 12 months.

Results. Of the 301 patients, anticoagulant therapy was prescribed to 166 (55.1 %), of which only 17 (10.2 %) people received proper anticoagulant therapy. The excessive activity was observed in 114 (37.9 %) patients, who underwent antiplatelet therapy with aspirin, and 21 (7.0 %) patients remained without any treatment with anticoagulants nor antiplatelet agents. Although, in the case of both, prescribing aspirin and not prescribing, anticoagulants have been indicated. In the prospective part of the study (for 12 months), all 45 patients continued to take anticoagulants and were systematically monitored. The INR in the target range over 60 % of the time was achieved in 37 % of patients receiving warfarin therapy.

Conclusion. In the actual clinical practice of Kyrgyzstan family medicine centers, older patients with atrial fibrillation receive inadequate antithrombotic therapy. The main drug of choice for specialists remains warfarin, a therapy that can be recognized as adequate only in a small number (16 %) of patients. The ability to improve the quality of surveillance and management of a group of patients with AF and high adherence to treatment was demonstrated by the work of a specialized team of doctors. 

1. Vavilova TV. Anticoagulants in clinical practice. Medical Board. 2015; 12: 44-47. (In Russ.). doi: 10.21518/2079-701X-2015-12-44-47

2. Kropacheva ES, Panchenko EP. Aspects of anticoagulant therapy in patients with atrial fibrillation in the light of updated guidelines of the European society of cardiology 2020: The position of dabigatran. Atherothrombosis. 2020; (2): 17-26. (In Russ.). doi: 10.21518/2307-1109-2020-2-17-26

3. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BHCh, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J. 2006; 27(8): 949-953. doi: 10.1093/eurheartj/ehi825

4. Rubanenko AO, Shchukin YuV. Factors associated with thrombosis of the left atrial appendage in patients with chronic atrial fibrillation. Klinicheskaya Medicina. 2014; 92(11): 29-34.

5. McGrath ER, Kapral MK, Fang J, Eikelboom JW, Conghaile Aó, Canavan M, et al.; Investigators of the Ontario Stroke Registry. Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology. 2013; 81(9): 825-832. doi: 10.1212/WNL.0b013e3182a2cc15

6. Turgunbaev DD, Artykbaev ASh, Kadyrova N, et al. Policy study document “Analysis of the verification of stroke diagnosis in persons died at home” Center for Health Policy Analysis. 2014; 23. URL: www.hpac.kg. (In Russ.)

7. Kanat kyzy Bazira, Musakeev AO, Mamatov SM, Kinderbayeva NK, Kundashev UK. Anticoagulant therapy of elderly people in the medical clinical activities of family medicine centers of the Kyrgyz Republic. Clinical gerontology. 2020; (9-10): 3-8. doi: 10.26347/1607-2499202009-10003-008. (In Russ.)

8. Belenkov YuN, Shakaryants GA, Khabarova NV, An GV. Anticoagulant therapy in elderly patients with atrial fibrillation. Cardiology. 2018; 58(10): 45-52. doi: 10.18087/cardio.2018.10.10177. (In Russ.)

9. Loukianov MM, Boytsov SA, Yakushin SS, Martsevich SYu, Vorobyev AN, Zagrebelnyy AV, et al. Diagnostic, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of atrial fibrillation in real outpatient practice. Rational Pharmacotherapy in Cardiology. 2014; 10(4): 366-377. (In Russ.)

10. Sokolova AA, Tsarev IL, Napalkov DA, Sulimov VA. Anticoagulant therapy in patients with atrial fibrillation: A state of the art in routine clinical practice. Trudnyy patsient. 2015; 7(13): 36-40. (In Russ.)

11. Sokolova AA, Zhilenko AV, Tsarev IL, Napalkov DA, Sulimov VA Practical aspects of the use of anticoagulant therapy in patients with atrial fibrillation of nonvalvular etiology: Data from the register of the university clinic. Rossiyskiy kardiologicheskiy zhurnal. 2015; 9(125): 32-37. (In Russ.)

12. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleedings rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use – learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis. 2014; 38(2): 150-159. doi: 10.1007/s11239-013-1048-z

13. Pirmohamed M, Burnside G, Eriksson N, Jorgensen A, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013; 369(24): 2294-2303. doi: 10.1056/NEJMoa1311386

14. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012; 125(16): 1997-2005. doi: 10.1161/CIRCULATIONAHA.111.070920

15. Lip GYH, Laroche C, Dan G-A, Santini M, Kalarus Z, Rasmussen LH, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: Baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. EP Europace. 2014; 16(3): 308-319. doi: 10.1093/europace/eut373

16. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complication of anticoagulant treatment. Chest. 2001; 19(1): 108-121

17. Sulimov VA, Napalkov DA, Sokolova AA, et al. Anticoagulant therapy in real clinical practice: Data from a retrospective one-step study. Ratsional’naya farmakoterapiya v kardiologii. 2015; 11(1): 116-123. doi: 10.20996/1819-6446-2015-11-2-116- 123. (In Russ.)

18. Arihiro S, Todo K, Koga M, Furui E, Kinoshita N, Kimura K, et al. Three-month risk benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke. 2016; 11(5): 565-574. doi: 10.1177/1747493016632239

19. Basaran Е, Dogan V, Biteker M, et al. Guideline-adherent therapy for stroke prevention in atrial fibrillation in different health care settings: Results from RAMSES study. Eur J Intern Med. 2017; 40: 50-55. doi: 10.1016/j.ejim.2017.02.011